T1	intervention 22 40	Mometasone Furoate
T2	condition 67 93	Acute Radiation Dermatitis
T3	control 275 295	Eucerin Original (E)
T4	eligibility 456 540	Breast cancer patients undergoing chest wall with or without nodal radiation therapy
T6	outcome-Measure 972 995	any grade ≥3 dermatitis
T7	outcome-Measure 1022 1068	time to occurrence of maximum-grade dermatitis
T8	outcome-Measure 1073 1103	patient-reported skin symptoms
T9	total-participants 1252 1255	124
T11	outcome 1659 1685	rate of moist desquamation
T12	iv-bin-percent 1790 1795	43.8%
T13	cv-bin-percent 1799 1804	66.7%
T14	outcome 1840 1876	incidence of maximum skin toxicities
T15	outcome 1899 1940	time to development of grade 3 dermatitis
T16	outcome 2016 2046	patient-reported skin outcomes
T17	iv-cont-mean 1942 1949	46 days
T18	cv-cont-mean 1953 1962	35.5 days
T5	outcome-Measure 837 878	development of provider-assessed grade ≥2
